Astellas Pharma Inc. ADR (ALPMY)
OTC PINK OTC PINK Primary 
XFRA Summary
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.
Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Astellas Pharma (ALPMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Astellas Pharma Inc. ADR (ALPMY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Astellas Pharma Inc. ADR ever had a stock split?
Astellas Pharma Inc. ADR Profile
| Pharmaceuticals Industry | Healthcare Sector | Naoki Okamura CEO | OTC PINK Exchange | 04623U102 CUSIP |
| JP Country | 14,754 Employees | 31 Mar 2026 Last Dividend | 13 May 2013 Last Split | - IPO Date |
Overview
Astellas Pharma Inc. is a distinguished player in the pharmaceutical industry operating not only domestically in Japan but also on an international scale. Founded in 1923 and with its headquarters nestled in Tokyo, Japan, the company has carved a niche for itself through the manufacturing, marketing, importing, and exporting of pharmaceuticals. Astellas's dedication to advancing medical care is proven through its consistent efforts in research and development, which has led to valuable collaborations. Notably, the company has formed a research collaboration with Vivtex Corporation to assess the potential of Vivtex's GI-ORIS screening and formulation technology. This partnership aims to enhance the oral delivery mechanisms of therapeutic candidates offered by Astellas. Additionally, a significant partnership with Roche Diabetes Care Japan Co., Ltd. showcases Astellas's commitment toward advancing diabetes care through the development and commercialization of an integrated diabetes self-management solution, cementing its role as an innovation-driven pharmaceutical powerhouse.
Products and Services
- XTANDI: A hallmark treatment manufactured by Astellas for prostate cancer. XTANDI stands out for offering patients a fighting chance against this prevalent disease, demonstrating Astellas's commitment to addressing critical oncological conditions.
- XOSPATA: This innovative medication is designed for patients suffering from relapsed or refractory acute myeloid leukemia harboring a FLT3 mutation, underscoring Astellas’s dedication to targeting specific genetic markers in cancer treatment.
- PADCEV: Representing a breakthrough in the treatment of metastatic urothelial cancer, PADCEV is indicative of Astellas’s leadership in developing therapies for complex oncological conditions.
- Evrenzo: A testament to Astellas’s emphasis on addressing chronic conditions, Evrenzo offers relief to patients grappling with anemia associated with chronic kidney disease.
- Betanis/Myrabetriq/BETMIGA: This product line caters to individuals facing the challenges of an overactive bladder. It underscores Astellas’s focus on improving the quality of life for patients dealing with everyday health conditions.
- Prograf and Advagraf/Graceptor/ASTAGRAF XL: These immunosuppressants are critical in the management of patients undergoing organ transplants, reflecting Astellas’s contribution to the field of transplant medicine and the importance of facilitating patient recovery and transplant success.
